Canine CAIX / CA9 Protein

Produkt-Information von CAIX / CA9 Protein

QC Testing von CAIX / CA9 Protein

Purity	>99% as determined by SDS-PAGE	SDS-PAGE: CAIX protein
Bio-activity	Measured by its esterase activity. The specific activity is > 10 pmoles/min/μg.
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Gln 38
Molecular Mass	The recombinant canine CA9/Fc is a disulfide-linked homodimer. The reduced monomer comprises 614 amino acids and has a predicted molecular mass of 67.6 kDa. The apparent molecular mass of the protein is approximately 79 kDa in SDS-PAGE under reducing conditions.
Formulation	Lyophilized from a 0.2μm filtered solution of Sterile 25 mM Tris, 0.15 M NaCl, pH 7.5. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von CAIX / CA9 Protein

Verwandte Produkte & Themen von CAIX / CA9 Protein

Cancer>>Cancer Biomarkers>>Carbonic Anhydrase IX

Enzyme>>Carbonic Anhydrase>>Carbonic Anhydrase IX

Beschreibung von CAIX / CA9 Protein

Carbonic anhydrases IX (CAIX), also known as membrane antigen MN or CA9, is a member of the carbonic anhydrase (CA) family and may be involved in cell proliferation and cellular transformation. CAs are zinc metalloenzymes that catalyze the reversible hydration of carbon dioxide ( H2O + CO2 = H+ + HCO3- ) and thus participate in a variety of biological and physical processes. CAIX is a transmembrane protein structurally consisting of a signal peptide, a proteoglycan-related region, a CA domain with a highly conserved active site, a transmembrane anchor and an intracytoplasmic tail, and is the only tumor-associated CA isoenzyme known so far. Compared with normal tissues, CAIX is overexpressed in a wide spectrum of tumor types and associated with increased metastasis and poor prognosis in aggressive carcinomas. CAIX expression is cell density dependent and has been shown to be strongly induced by hypoxia, accordingly facilitates adaptation of tumor cells to hypoxic conditions. CA9 is regarded as a new therapeutic target for CA9-derived carcinomas.

References

1. Pastorek J. et al., 1994, Oncogene. 9: 2877-88.
2. Opavsky R. et al., 1996, Genomics. 33: 480-7.
3. Swietach P. et al., 2008, J Biol Chem. 283: 20473-83.
4. Robertson N. et al., 2004, Cancer Res. 64: 6160-5.
5. Bui MH. et al., 2003, Clin Cancer Res. 9: 802-11.
6. Choi SW. et al., 2008, Hum Pathol. 39: 1317-22.

Sino Biological Inc. liefert Canine CAIX / CA9 Protein mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Canine CAIX / CA9 Protein lesen Sie bitte: http://www.sinobiological.com/CAIX-CA9-Protein-g-9545.html